Anti-Inflammatory Effects of Idebenone Attenuate LPS-Induced Systemic Inflammatory Diseases by Suppressing NF-κB Activation

• Published in: Antioxidants 2024-01, Vol.13 (2), p.151
• Main Authors: Choi, Yumin, Cho, Young-Lai, Park, Sujeong, Park, Minkyung, Hong, Keun-Seok, Park, Young Jun, Lee, In-Ah, Chung, Su Wol, Lee, Heedoo, Lee, Seon-Jin
• Format: Article
• Language: English
• Subjects: Alcohol; Animal models; anti-inflammation; Anti-inflammatory agents; Anti-inflammatory drugs; Antibiotics; Antioxidants; Cecum; Cognitive ability; Cytokines; Dementia; Dementia disorders; Drug therapy; Enzymes; Ethylenediaminetetraacetic acid; Health aspects; idebenone; Immune system; Infection; Infections; Inflammation; inflammatory disease model; Inflammatory diseases; Irritation; Lipid peroxidation; Lipopolysaccharides; Macrophages; Metabolism; NF-κB; NF-κB protein; Reactive oxygen species; ROS; Scientific equipment and supplies industry; Sepsis; Signal transduction; Tumor necrosis factor-TNF
• ISSN: 2076-3921; 2076-3921
• DOI: 10.3390/antiox13020151

Inflammation is a natural protective process through which the immune system responds to injury, infection, or irritation. However, hyperinflammation or long-term inflammatory responses can cause various inflammatory diseases. Although idebenone was initially developed for the treatment of cognitive impairment and dementia, it is currently used to treat various diseases. However, its anti-inflammatory effects and regulatory functions in inflammatory diseases are yet to be elucidated. Therefore, this study aimed to investigate the anti-inflammatory effects of idebenone in cecal ligation puncture-induced sepsis and lipopolysaccharide-induced systemic inflammation. Murine models of cecal ligation puncture-induced sepsis and lipopolysaccharide-induced systemic inflammation were generated, followed by treatment with various concentrations of idebenone. Additionally, lipopolysaccharide-stimulated macrophages were treated with idebenone to elucidate its anti-inflammatory effects at the cellular level. Idebenone treatment significantly improved survival rate, protected against tissue damage, and decreased the expression of inflammatory enzymes and cytokines in mice models of sepsis and systemic inflammation. Additionally, idebenone treatment suppressed inflammatory responses in macrophages, inhibited the NF-κB signaling pathway, reduced reactive oxygen species and lipid peroxidation, and normalized the activities of antioxidant enzyme. Idebenone possesses potential therapeutic application as a novel anti-inflammatory agent in systemic inflammatory diseases and sepsis.